- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00129623
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
5 december 2015 uppdaterad av: Hoffmann-La Roche
Double-blind, Placebo-controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of Oral Ibandronate Once Monthly in Postmenopausal Women With Osteopenia
This 2 arm study will evaluate the efficacy and safety of oral Bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia.
Patients will be randomized to receive either Bonviva 150mg po monthly, or placebo monthly.
The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
160
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Colorado
-
Lakewood, Colorado, Förenta staterna, 80227
-
-
Florida
-
Stuart, Florida, Förenta staterna, 34996
-
-
Maryland
-
Bethesda, Maryland, Förenta staterna, 20817
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48236
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68131
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87106
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45224
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97213
-
-
Texas
-
Amarillo, Texas, Förenta staterna, 79124
-
-
Virginia
-
Norfolk, Virginia, Förenta staterna, 23502
-
Richmond, Virginia, Förenta staterna, 23294
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
45 år till 60 år (Vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Kvinna
Beskrivning
Inclusion Criteria:
- women 45-60 years of age;
- post-menopausal;
- ambulatory.
Exclusion Criteria:
- vertebral fracture (except traumatic fracture such as in a motor vehicle accident);
- low-trauma osteoporotic fracture in any other bone;
- breast cancer diagnosed within last 20 years;
- other malignancy diagnosed within last 10 years, except successfully resected basal cell cancer;
- treatment with any bisphosphonate within last 2 years;
- treatment with other drugs affecting bone metabolism within last 6 months.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 1
|
150mg po monthly for 1 year
|
Placebo-jämförare: 2
|
po monthly for 1 year
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Relative Change From Baseline in Mean Bone Mineral Density (BMD) of the Lumbar Spine (L2 to L4) at Month 12
Tidsram: Baseline and Month 12
|
BMD was measured by a single dual-energy x-ray absorptiometry (DEXA) scan of the lumbar spine at the time of screening and at Month 12.
A BMD measurement was considered unsuitable in case of detection of a fracture, an osteoarthritic process, or a scanning artifact that could not be removed to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center.
The change in BMD was defined as the relative difference between the last individual measurement available at 12 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at baseline) / (BMD at baseline)
|
Baseline and Month 12
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Absolute Change From Baseline in Mean Lumbar Spine BMD at Month 12
Tidsram: Baseline and Month 12
|
BMD was measured by a single dual-energy x-ray absorptiometry (DEXA) scan of the lumbar spine at the time of screening and at Month 12.
A BMD measurement was considered unsuitable in case of detection of a fracture, an osteoarthritic process, or a scanning artifact that could not be removed to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center.
The absolute change from Baseline in mean BMD of the lumbar spine (L2-L4) was measured as g/cm^2 and summarized using descriptive statistics.
|
Baseline and Month 12
|
Relative Change From Baseline in Mean Proximal Femur BMD at Month 12
Tidsram: Baseline and Month 12
|
BMD was measured by a single DEXA scan of the proximal femur at the time of screening and at Month 12.
The relative (%) change from Baseline in BMD of the proximal femur (total hip, trochanter, femoral neck) at Month 12 was summarized using descriptive statistics.
BMD of fractured bones that could impact the scan area were not taken into account.
|
Baseline and Month 12
|
Absolute Change From Baseline in BMD of the Proximal Femur at Month 12
Tidsram: Baseline and Month 12
|
BMD was measured by a single DEXA scan of the proximal femur at the time of screening and at Month 12.
The absolute change from baseline in BMD of the proximal femur (total hip, trochanter, femoral neck) at Month 12 was summarized using descriptive statistics.
BMD of fractured bones that could impact the scan area were not taken into account.
|
Baseline and Month 12
|
Relative Change From Baseline in Serum C-telopeptide Crosslinks of Type 1 Collagen (CTX)
Tidsram: Baseline and 3, 6 and 12 months
|
Fasting blood samples were collected from participants for analysis of serum CTX (sCTX), which is a biochemical marker of bone resorption.
Relative change from baseline of sCTX after 3, 6, and 12 months of treatment was summarized using descriptive statistics.
|
Baseline and 3, 6 and 12 months
|
Absolute Change From Baseline in sCTX
Tidsram: Baseline and 3, 6, 12 months
|
Fasting blood samples were collected from participants for analysis of sCTX, which is a biochemical marker of bone resorption.
Absolute change from baseline of sCTX after 3, 6, and 12 months of treatment was summarized using descriptive statistics.
|
Baseline and 3, 6, 12 months
|
Percentage of Responders
Tidsram: Up to 12 months
|
Percent responders were defined as follows: Participants with a) lumbar spine (LS) BMD, equal to or above Baseline at Month 12 b) proximal femur BMD, equal to or above Baseline at Month 12 c) Both lumbar spine and proximal femur BMD, equal or above Baseline at Month 12. BMD of the lumbar spine was defined as the BMD of at least two vertebrae (L2-L4) that were not fractured and not affected by an osteoarthritic process, or a scanning artifact that could not be removed to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center.
Proximal femur included total hip, trochanter and femoral neck sites.
|
Up to 12 months
|
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: Up to 15 days after end of study treatment (Approximately 2 years)
|
An AE is any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
A serious adverse event is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
|
Up to 15 days after end of study treatment (Approximately 2 years)
|
Number of Participants With Marked Laboratory Abnormalities
Tidsram: Screening up to 12 months
|
Blood for laboratory tests was taken at screening and immediately before participants received their monthly study medication at months 3, 6, and 12.
The laboratory tests included: Hematology [white blood cells (WBCs), platelets, hematocrit, and hemoglobin] and Chemistry [albumin, creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), total calcium, 25-hydroxy vitamin D, phosphate, magnesium, sodium, potassium, and chloride].
|
Screening up to 12 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 december 2005
Primärt slutförande (Faktisk)
1 december 2007
Avslutad studie (Faktisk)
1 december 2007
Studieregistreringsdatum
Först inskickad
11 augusti 2005
Först inskickad som uppfyllde QC-kriterierna
11 augusti 2005
Första postat (Uppskatta)
12 augusti 2005
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
11 januari 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
5 december 2015
Senast verifierad
1 december 2015
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- BA18492
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Postmenopausal osteopeni
-
University of ReadingHar inte rekryterat ännuPost menopausalStorbritannien
-
University of ReadingOkändPost menopausal | Benförlust, ålder fastställdStorbritannien
-
University of PittsburghNational Institute on Aging (NIA)AvslutadPost menopausalFörenta staterna
-
Seoul National University Bundang HospitalJW PharmaceuticalAvslutadHyperkolesterolemi | Osteoporos, osteopeni | Menopausal osteoporosKorea, Republiken av
-
Riphah International UniversityRekryteringPost menopausalPakistan
-
AstraZenecaAvslutadBröstcancer | Post menopausalItalien
-
National Institute of Mental Health (NIMH)AvslutadDepression | Friska | Perimenopausal depression | Post menopausalFörenta staterna
-
AstraZenecaAvslutad
-
St. Joseph's Healthcare HamiltonOntario Mental Health FoundationAvslutad
-
Laval UniversityV Joseph; C Minville; C RheaumeRekryteringSömnapné | Oxidativ stress | Post menopausalKanada
Kliniska prövningar på ibandronate [Bonviva/Boniva]
-
GlaxoSmithKlineAvslutadOsteoporosKorea, Republiken av
-
Hoffmann-La RocheAvslutadSmärta | Neoplasma Metastas | BenneoplasmaFörenta staterna, Mexiko, Tyskland, Ryska Federationen, Italien, Ungern, Belgien, Chile, Frankrike, Argentina, Australien, Schweiz, Guatemala, Puerto Rico, Polen, Panama, Storbritannien, Kanada
-
Hoffmann-La RocheIndragenSmärta | Neoplasma Metastas | BenneoplasmaGrekland
-
Hoffmann-La RocheAvslutadSmärta; Benneoplasmer; Neoplasma MetastaserKalkon
-
Chinese Society of Lung CancerAvslutad
-
Chinese University of Hong KongAvslutadSystemisk lupus erythematosusKina
-
Hoffmann-La RocheAvslutadSmärta | Neoplasma Metastas | BenneoplasmaFörenta staterna, Italien, Chile, Ryska Federationen, Ungern, Storbritannien, Polen, Guatemala, Tyskland, Mexiko, Puerto Rico, Grekland, Australien, Schweiz, Argentina, Panama
-
University Hospital, LinkoepingAvslutad
-
Charite University, Berlin, GermanyAvslutadOsteoporos, postmenopausalTyskland